FDA Approves First PROTAC Therapy for Breast Cancer

The FDA has approved vepdegestrant (Veppanu), marking a milestone in oncology drug development as the first authorized PROteolysis TArgeting Chimera (PROTAC) therapy for clinical use.The drug, developed by Arvinas in collaboration with Pfizer, is indicated for adults with estrogen receptor–positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on at least one line of endocrine therapy.¹

The approval was granted ahead of its June 2026 Prescription Drug User Fee Act target date, underscoring both the urgency of unmet need in this patient population and the growing clinical confidence in targeted protein degradation as a therapeutic modality.

Addressing endocrine resistance in breast cancer

Hormone receptor–positive breast cancer remains the most common subtype globally, with endocrine therapies forming the backbone of treatment. However, resistance frequently develops, often driven by mutations in the estrogen receptor gene (ESR1). These mutations occur in approximately 40%–50% of patients treated with endocrine therapy combined with CDK4/6 inhibitors and are associated with poorer outcomes and limited second-line options.^1,2

Veppanu directly targets this resistance mechanism by degrading the estrogen receptor protein rather than merely inhibiting it. This approach distinguishes PROTACs from traditional small-molecule inhibitors and selective estrogen receptor degraders, potentially enabling more complete suppression of oncogenic signaling.³

VERITAC-2 data demonstrate clinical benefit

The FDA decision was based on results from the Phase 3 VERITAC-2 trial, which compared Veppanu with fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. Among patients with ESR1 mutations (n=270), Veppanu reduced the risk of disease progression or death by 43% relative to fulvestrant (hazard ratio 0.57; p=0.0001).¹

Median progression-free survival (PFS) was 5.0 months for Veppanu versus 2.1 months for fulvestrant, representing a clinically meaningful improvement in a setting where treatment options are limited.¹ These findings align with broader efforts to improve outcomes in endocrine-resistant disease, where incremental gains are considered clinically relevant.²

The safety profile was generally manageable, with most adverse events reported as Grade 1 or 2. Common toxicities included hematologic abnormalities, elevated liver enzymes, fatigue, and gastrointestinal effects. Notably, QT interval prolongation was identified as a potential risk requiring monitoring.¹

A new modality: targeted protein degradation

PROTACs represent a novel therapeutic class that leverages the cell’s ubiquitin-proteasome system to selectively degrade disease-causing proteins. Unlike conventional inhibitors, which require sustained target occupancy, PROTACs act catalytically, potentially enabling lower dosing and broader target engagement.^3,4

The approval of Veppanu provides the first clinical validation of this mechanism, which has been under development for more than a decade. Early research has suggested that targeted protein degradation may overcome resistance mechanisms that limit the efficacy of traditional therapies, particularly in oncology.³

Beyond breast cancer, PROTAC-based approaches are being explored across a range of therapeutic areas, including neurodegenerative and neuromuscular diseases, reflecting the versatility of the platform.⁴

Clinical and commercial outlook

From a clinical perspective, Veppanu introduces a new oral treatment option in a setting where injectable therapies such as fulvestrant have been standard. This may offer both convenience and improved adherence for patients requiring long-term therapy.

Arvinas and Pfizer plan to collaborate with a third-party partner to support commercialization and maximize global access. The companies have indicated that partner selection is ongoing and expected to be announced in the near term.¹

While longer-term data, including overall survival outcomes, remain immature, the initial clinical results support further development of PROTAC-based therapies and highlight their potential to reshape treatment paradigms in hormone-driven cancers, according to trial investigators.

References

1. Arvinas announces FDA approval of VEPPANU (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer. (2026, May 1). Arvinas. https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-approval-veppanu-vepdegestrant-treatment
2. Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015 Jun 30). ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2015.117
3. Pettersson, M., & Crews, C. M. (2019 Apr). PROteolysis TArgeting Chimeras (PROTACs)—past, present and future. Drug Discovery Today: Technologies. https://doi.org/10.1016/j.ddtec.2019.01.002
4. Békés, M., Langley, D. R., & Crews, C. M. (2022 Jan 18). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-021-00371-6